載入中
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
前收盤價
US$0.305
+US$0.0008 · +0.26%
盤後
US$0.3079
+US$0.0029 · +0.95%
10月12日 下午7:51 ET
盤中時間採用ET。市場資料可能有所延遲。
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
日內區間
目前US$0.305
52週區間
目前US$0.305
盤中時間採用ET。市場資料可能有所延遲。
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
日內區間
目前US$0.305
52週區間
目前US$0.305
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 3185.63萬 USD | 2270.13萬 USD | 1778.27萬 USD | 709.12萬 USD | 380.51萬 USD |
| 銷售、一般及管理費用 | 784.64萬 USD | 722.26萬 USD | 728.99萬 USD | 779萬 USD | 363.29萬 USD |
| 營業費用 | 3970.26萬 USD | 2992.39萬 USD | 2507.26萬 USD | 1538.12萬 USD | 1052.58萬 USD |
| 利息收入 | 337.85萬 USD | 320萬 USD | 116.4萬 USD | 54.73萬 USD | 64.24 USD |
| 利息支出 | — | — | — | 54.73萬 USD | 6.42萬 USD |
| 折舊和攤銷 | 1.63萬 USD | 1.09萬 USD | 1.2萬 USD | 9268 USD | −308.78萬 USD |
| 營業利益 | −3970.26萬 USD | −2992.39萬 USD | −2507.26萬 USD | −1538.12萬 USD | −1052.58萬 USD |
| 淨利 | −3612.36萬 USD | −2672.51萬 USD | −2396.42萬 USD | −1483.59萬 USD | −1045.69萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI109.72萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM71.83萬0.00%787.4億 USD0.19%US$277.9-0.37%
iShares Russell 2000 Growth ETFIWO26.51萬0.00%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO21.06萬0.00%180億 USD0.06%US$112.27-0.35%
Vanguard Extended Market ETFVXF20.3萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC9.02萬0.01%13.17億 USD0.60%US$181.66-0.73%
Vanguard Russell 2000 Growth ETFVTWG3.94萬0.00%17億 USD0.06%US$258.28-0.85%
iShares Russell 2500 ETFSMMD1.52萬0.00%40.62億 USD0.23%US$86.01-0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
